Scientific article: FcgRs modulate the anti-tumor activity of anti-PD-1/PD-L1 antibodies

by | Mar 26, 2024 | Cancer, Immunology, in vivo Studies, Neurology


FcgRs Modulate the Anti-tumor Activity of anti-PD-1/PD-L1 Antibodies

Bio X Cell has recently published a scientific article featuring a journal publication that highlights the value of considering Fc domain interactions in research and development of therapeutic antibodies. 

Read more about the publication summary, have a glance at some featured anti-PD-1, anti-PD-L1 antibodies and recombinant antibodies for your next research project from Bio X Cell, as well as explore additional Bio X Cell immune checkpoint antibodies.


Antibodies For In Vivo Research

Bio X Cell antibodies are formulated for in vivo experiments and used extensively in animal models of human disease. They feature greater than 95% purity, ultra-low endotoxin levels, and are presevative, stabilizer, and carrier protein-free. Bio X Cell has developed a wide range of antibodies for immuno-oncology, immunology, and neuroscience research. Their products are cited in over 15,000 publications that detail a broad range of applications, including in vivo cell-specific depletion, cytokine neutralization, immune checkpoint blockade, and more.


    • Exceptional Purity
    • Pathogen Free
    • Ultra-low Endotoxin Level
    • Advanced Binding Validation
    • Low Protein Aggregation
    • Marching Isotype Control Antibodies

All products listed on this site and sold through LAB-A-PORTER Limited are for research use only (RUO). Not for human use. Not for therapeutic or diagnostic use.


  1. Bio X Cell, ‘FcgRs Modulate the Anti-tumor Activity of anti-PD-1/PD-L1 Antibodies’ Available at

Learn more on our comprehensive in-vivo research reagents today.

Contact us
Share This